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Internet websites are a resource for patients seeking information about probiotics. We examined a sample of 71
websites presenting probiotic information. We found that descriptions of benefits far outnumbered descriptions of
risks and commercial websites presented significantly fewer risks than noncommercial websites. The bias towards
the presentation of therapeutic benefits in online content suggests that patients are likely interested in using
probiotics and may have unrealistic expectations for therapeutic benefit. Gastroenterologists may find it useful to
initiate conversations about probiotics within the context of a comprehensive health management plan and should
seek to establish realistic therapeutic expectations with their patients.
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A recent analysis by the Pew Internet & American Life
Project found that 80% of Internet users in the U.S.
search the Internet to obtain health-related information
[1]. Those who are living with chronic disease report
going online to search for health related information at a
slightly higher rate (83%) [1]. These trends reflect the
increasing popularity of the Internet as a key source of
information about health and highlight the need for phy-
sicians to be familiar with the content of health-related
websites their patients may be accessing [2-5].
Like many patients with chronic illness, individuals
with gastrointestinal (GI) diseases often turn to the
Internet for information on treatment options [6]. Of
particular interest to many patients living with inflam-
matory bowel disease (IBD), irritable bowel syndrome
(IBS), and other chronic GI diseases is the potential uti-
lity of probiotics and other so-called complementary and
alternative medicines [7]. Patients can purchase probio-
tics directly and the marketing of these products is not
regulated by the Food and Drug Administration (FDA)
in a manner that is comparable to the regulation of
pharmaceutical drugs. These considerations highlight
the need to examine Internet messages about probiotics.
Knowing what information is communicated to patients,
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reproduction in any medium, provided the orother clinicians who care for patients with chronic GI
diseases, many of whom are using probiotics or may be
considering their use as a supplement to ongoing care
regimens [7-10].
We present a systematic description of Internet websites
discussing probiotics. Our analysis describes: 1- Internet
depictions of the potential benefits and risks of probiotics;
2- common misrepresentations of probiotics; and, 3- other
information that may influence patient decisions about
the use of probiotics. To the extent that these Internet
messages may shape patient attitudes and beliefs, gastro-
enterologists should be aware of how the potential bene-
fits and risks of probiotics are being presented to the
patients they serve. By understanding the full spectrum of
Internet messages concerning probiotics, gastroenterolo-
gists can better engage their patients in discussions about
probiotics and their potential use as a tool for managing
chronic GI diseases.
We constructed a sample of probiotic-related websites
using criteria that would mirror the search patterns of
patients with GI diseases. Online searches were completed
initially using the five most popular search engines at the
time of sampling—Google, Yahoo, LiveSearch, AOL, and
Ask [11]. Due to the similar search algorithms employed
by these five search engines, keyword searches using the
term “probiotics” returned similar results. Therefore, we
chose to rely on two popular search engines, Google and
Yahoo, in identifying relevant Internet websites. We
conducted Internet queries using these search engines
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health information searches are typically limited to initial
search results, we limited our sample to the first 50 results
of each search engine query (5 pages of results per query)
[12]. Websites were excluded from the sample if the web-
site: 1- existed solely as a retail site intended for direct pur-
chase; 2- was not able to be accessed at the time of sample
selection; 3- was determined to be an erroneous result
upon closer examination (e.g. a clearly unrelated website
with no content related to probiotics); 4- focused on non-
human applications of probiotics; or 5- was a peer reviewed
scientific, medical, or research article or book (Figure 1).
Due to the highly dynamic nature of online content,
discrete images of each website were saved as PDF files
along with the date on which the content was captured.
Two analysts independently reviewed each of these files
using a code sheet to document specific content areas
and qualities of the websites. A code sheet was deve-
loped and used to evaluate major content areas (Table 1).
The Sandvik scale was used to evaluate overall website
quality based on seven characteristics measured on a
scale from 0-worst to 2-best [13]. These results were
then summed for a best possible score of 14 [13].
After two analysts independently coded websites for
content, their respective code sheets were compared and
used to establish a single consensus code sheet. Cohen’s
kappa statistic was used to evaluate agreement between
the two analysts and showed very high levels of agree-
ment across the 10153 items (143 items per website)
evaluated [14]. Kappa values for each of the 71 websitesFigure 1 Description of Sampling Methods.ranged from 0.41 to 0.94, with a mean value of 0.72 and
standard deviation of 0.10. Results were entered into an
Access database and imported into SPSS version 19.0 for
further analysis [15]. Descriptive statistics were examined
to check for outliers and data-entry errors. Independent
samples t-tests (for ordinal data) and Fisher’s exact tests
(for nominal data) were used to assess differences between
commercial and noncommercial websites. P values of < 0.05
were considered statistically significant.
A total of 71 websites were identified and analyzed for
content. As shown in Table 2, these websites were di-
verse with respect to content and intended audience.
Approximately half of the websites (51%) were categor-
ized as commercial. Websites that were not commercial
in nature included those run by non-profit organizations
(13%), news media (13%), Internet content farmsa (4%),
and personal websites (4%). Two websites included in
the sample were maintained by medical institutions, one
from the Mayo Clinic and another from the University
of Alabama Health System. The only government site
included in the analysis was supported by the National
Center for Complementary and Alternative Medicine.
A majority of these websites (76%) identified at least
one probiotic product using a commercial brand name.
It was also common for websites to have some connec-
tion or “linkage” to more information about a specific
probiotic product (72%) (Table 2). Many of those links
were to product advertisements (75%). Other links direc-
ted readers to outside websites where probiotic products
could be purchased (47%).
Table 1 Coding categories used to analyze the content of
71 Internet websites on probiotics
Content Domain Research Question
Framework How are probiotics being defined for the reader?
Mechanism of
Action
By which biologic mechanisms do probiotics function
within the body?
Product What products are mentioned and how much detail
is given about their contents?
Regulation How is the regulatory status of probiotics described (if
at all)?
Benefits What benefits are attributed to using probiotics?
Risks What risks are attributed to using probiotics?
Research What research about probiotics is described (if any)?
References What types of materials are cited (if any)?
Tone Is there a clear recommendation for or against
probiotic use? How is this conveyed?
Accessibility In what ways is the website connected to additional
information and probiotic products?
Website
Characteristics
Describe the structure and functionality of the website
itself.
Sandvik Scale A 7-item instrument used to rate the overall quality of
a website.








content farms 3 (4)
personal 3 (4)
healthcare institution 2 (3)
government 1 (1)
Information Provided
organization maintaining web address 67 (94)
year established 58 (82)







other organization 8 (11)
voluntary health organization 8 (11)
medical institution 6 (9)
professional organization 6 (9)
media 4 (6)
Link to Products
at least 1 link to a probiotic product 51 (72)
advertisement 38 (75)
link to outside url to purchase 24 (47)
information on where to purchase 17 (33)
direct purchase 14 (28)
Sponsorship
returned as sponsored link 12 (17)
Contact Information
provides contact information 58 (82)
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lity, the Sandvik score set a mean overall quality score at
9.3 (Table 3). When commercial and noncommercial web-
sites were compared, their Sandvik scores differed signi-
ficantly with mean scores of 7.7 and 10.7 respectively
(p=.001). Commercial websites received consistently lower
mean ratings than their noncommercial counterparts in
six of the seven content areas examined using the Sandvik
scale, including “balance,” “authorship,” and “currency” of
content, with significantly lower mean scores across each
of these three areas (p=.001).
Websites were generally accurate in their depictions of
what probiotics are and how they function in the host
(Table 4). Probiotics typically were described as “comple-
mentary” to other approaches to promoting good health.
Although a widely accepted definition of probiotics
recommended by the Food and Agricultural Organization
of the United Nations and World Health Organization
(FAO-WHO) was not used consistently across websites,
over half of the websites did contain all four components
of this definition (56%). Two primary elements of this
definition, that probiotics are “live microorganisms” (89%)
ingested to provide “health benefit” (86%), were present in
most websites. Websites often suggested that probiotics
may provide benefits related to general health and well-
ness (70%) as well as improvements in GI health (96%).
The description of probiotics as consumable products
almost uniformly included some mention of the species
(94%) and manner in which it is to be ingested (99%). In
addition to defining what probiotics are and suggesting
appropriate indications for their use, all but one websitenoted at least one mechanism of action by which probiotic
bacteria function in the host. The two most common
mechanisms described were to regulate immune response
(83%) and inhibit pathogenic bacteria colonization (82%).
Focus on therapeutic benefit
The representation of potential benefits and risks varied
greatly across websites (Table 5). Seventy percent of
websites identified at least one specific disease or clinical
indication for probiotics. Specific benefits cited ranged
from relieving general gastrointestinal distress such as gas
and bloating (n=63), to managing behavioral symptoms
Table 3 Comparison of general quality criteria scores




Ownership 1.81 1.91 .319
Source 1.33 1.51 .336
Interactivity 1.33 1.23 .507
Balance 0.28 1.69 .001
Authorship 0.50 1.26 .001
Currency 0.94 1.60 .001
Navigability 1.58 1.69 .405
Total Score* 7.72 10.74 .001
* Each Sandvik criterion is scored on a scale of 0 to 2, for a total score of 0
(worst)-14 (best).
Table 5 Specific benefits and risks of probiotics described
on 71 Internet websites*
Benefits Risks
Allergies GI (minor, e.g. wind, bloating)
Candida Safety Issues for Children
Cholesterol Levels Safety Issues for Immunocompromised
Colitis Safety Issues for Pregnant
Diarrhea-other Safety Issues for those with Underlying
Health Issues
Eczema
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ease (n=4). Specific risks associated with probiotics were
noted less frequently than benefits and typically focused
on minor GI issues such as the potential for diarrhea or
gas (n=28). A few websites also discussed less common
risks related to bacterial infection (n=7) and headaches
(n=4). Other potential safety issues focused on heightened
risks for specific populations, such as probiotic use by
children (n=20) and pregnant women (n=13). Of the web-
sites examined, 47% did not mention any risks associated
with probiotic use.Table 4 Characterizations of probiotics on 71 Internet
websites
N (%)
Defined Using Elements of the FAO-WHO Definition*
contain all 4 components of FAO-WHO definition 40 (56)
live microorganisms 63 (89)
administered to host 53 (75)
adequate amounts 42 (59)
health benefits 61 (86)
Probiotics Function By
regulating local immune response 59 (83)
regulating inflammatory response 26 (37)
improving gut’s barrier function 26 (37)
inhibiting pathogenic bacteria colonization 58 (82)
other 28 (39)
Indications for Use
improve general health 50 (70)
improve GI health 68 (96)
Product
strain of bacteria noted 67 (94)
general vehicle for consumption noted 70 (99)
specific brand named 54 (76)
* The FAO-WHO defines probiotics as live microorganisms which when











* These benefits and risks were cited by at least 10% of the 71 Internet
websites examined. An additional 49 benefits and 22 risks were cited on these
websites but not on at least 10% of the total sample and are not listed above.
† The benefits listed in bold appeared on more than 50% of the 71 Internet
websites examined. No risks were described on more than 50% of the websites.On average, websites mentioned 10.2 benefits and 1.8
risks per website, with an upper range of 36 benefits and
11 risks on any individual site (Table 6). The number of
risks described on commercial websites was significantly
lower than noncommercial websites (1.0 and 3.0 respec-
tively; p=.002). Although no formal evaluation was per-
formed, websites often reiterated one or more benefits
of using probiotics multiple times throughout the text.
Conversely, the discussion of risks associated with
probiotics was less commonly reiterated in multiple
locations.
Table 6 A comparison of how commercial and
noncommercial websites portray probiotics
N (%)
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† Fisher’s exact test.
‡ Student’s T-test.
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appeared in approximately half (49%) of the websites
reviewed (Table 6). Broad statements of general health
benefit—such as claims that probiotics can help “Maintain
optimal health and wellness”—were present in more than
half of the websites (59%). Commercial websites were
significantly more likely to include such a statement (62%)
in comparison to noncommercial websites (32%) (p=.031).
Nearly half (47%) of the websites encouraged readers to
discuss probiotics with a heath care provider and 56% ex-
plicitly endorsed the use of probiotics (Table 6). These
endorsements were often made by an identifiable individ-
ual, such as a named physician (23%), other medical pro-
fessional (31%) or patient/consumer (21%). Commercialwebsites were more likely to recommend the use of pro-
biotics than noncommercial websites (p=.001).
When gastroenterologists and other healthcare provi-
ders (HCPs) encounter patients who are interested in
using probiotics as therapy for their GI disease, they
should anticipate that many of these patients will have
been exposed to a variety of messages concerning the
health benefits of probiotics. Our data indicate that many
Internet websites contain unsubstantiated and misleading
claims about the therapeutic benefits of probiotics. This
benefit-focused messaging is particularly troubling given
that probiotics have not been studied extensively in
clinical trials and there is little to no evidence supporting
many of the benefits claimed on some websites. For
example, although there is evidence suggesting that pro-
biotic bacteria may have some utility in the care of
patients with IBS, ulcerative colitis, and pouchitis [16-21],
claims that probiotics can prevent cancer or assist in
managing autistic behaviors lack empirical support.
In addition to unsupported claims of benefit, our ana-
lysis also revealed a comparative lack of information
about the risks of using probiotics. Studies suggest that
the level of risk posed to healthy individuals by a typical
probiotic is very low [22]. In the absence of high quality
data documenting harms associated with typical uses of
probiotics, the lack of online information about possible
side effects is unsurprising. For some individuals, how-
ever, such as immunocompromised patients who may be
seeking probiotics to manage a chronic GI disease, there
may be additional risks that are not discussed on most
Internet websites [23-27].
Effective patient communication amid mixed health
messages
Alongside the specific health benefits noted above, our
analysis identified many broad statements promoting
probiotics as a general wellness tool. The promotion of
probiotics as a holistic “complementary and alternative
medicine” (CAM) situates these products in a market
space occupied primarily by healthy consumers seeking
to prevent disease and maintain overall health and well-
ness. Unfortunately, a number of studies have demon-
strated that patients often are reluctant to discuss their
interest in CAM with physicians [28-32]. In the case of
probiotics, wellness messaging on Internet websites may
make patients less likely to consult with a HCP prior to
using probiotics. By employing a combination of market-
ing messages, focusing on both specific symptom man-
agement and promotion of overall health, probiotic
products are depicted as both benign CAM and as
powerful disease management tools, even within the
very same website. This dual messaging may create con-
fusion among patients with chronic GI diseases, who
may wonder where these products fit within the context
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these patients may discontinue medication use without
consulting a gastroenterologist, in favor of over-the-
counter probiotic products.
The difference in language used to market probiotics
to healthy consumers contrasts with marketing strategies
designed to elicit interest among patients with chronic
GI diseases. In a study by Mercer and colleagues, when
GI patients were asked to comment on their personal
perceptions of the risks and benefits of probiotics, the
authors found that many GI patients were reluctant to
initiate new treatments, even over-the-counter treat-
ments, without consulting their physicians [7]. Mercer
and colleagues also found that patients expressed con-
cerns that while probiotics may be effective in promot-
ing good digestive health for many individuals, as
patients with chronic GI diseases, they felt they needed
to exercise greater caution in using products that affect
digestive balance. For many of these patients, claims of
improved digestive health were not sufficient to motivate
probiotic use.
Another source of inconsistent online messaging about
probiotics is evident in the frequent suggestion that indi-
viduals consult a physician or other medical professional
prior to using probiotics. Although the importance of
seeking advice from a physician was explicit on many
websites this message frequently was accompanied by
tips on where to purchase over-the-counter probiotics
or invitations to purchase probiotics online. While sug-
gestions to bring physicians into decisions about the use
of probiotics may temper patient’s enthusiasm to pur-
chase probiotics independently, appeals to physician in-
volvement may also suggest greater levels of medical
benefit than are supported by available data.
We suggest that the responsibility to clarify the poten-
tial benefits and risks of probiotic therapies falls squarely
in the hands of health care providers. By discussing pro-
biotics with patients in a nonjudgmental manner that is
mindful of the many mixed messages that patients may
have received concerning these products, HCPs can help
patients assess what role, if any, probiotics should play
in their ongoing treatment approach.
Commercial interests
The complex and sometimes inconsistent mix of mes-
sages about probiotics presented online are further com-
plicated by a strong presence of commercial interests in
many of the websites patients may view. Structurally
these sites interface closely with probiotic marketing and
frequently identify specific brands or products by name.
Even when patients are not offered the opportunity to
purchase a particular product online, our data shows
that online searches will often include multiple websites
promoting the use of probiotic products. The influenceof commercial interests is of particular concern since the
overall quality of commercial websites, as measured by
the Sandvik score, was significantly lower in comparison
to websites that lacked a commercial focus. Many com-
mercial websites failed to identify an author, failed to
indicate how current the information contained on the
site was, and lacked balance. These findings suggest that
HCPs should be cautious in promoting any particular
product and direct interested patients to more balanced,
higher quality websites maintained by noncommercial
entities.
In an era when direct-to-consumer advertising plays a
major role in the marketing of pharmaceutical drugs
[33,34], the strategies employed on probiotic websites
are not surprising. In addition, manufacturers’ claims
regarding the efficacy of probiotic products are not sub-
jected to the rigorous oversight typical of pharmaceutical
drugs [35]. Nonetheless, references to peer-reviewed
medical literature appeared in the majority of the web-
sites we reviewed (63%). The presence of such citations
implies a certain degree of scientific validity behind
claims of safety or efficacy, regardless of the accuracy of
the specific statements made or relevance of the studies
cited. In a best case scenario, potential inconsistencies
between available research data and claims of health
benefit would be discussed in a clinical setting, with the
involvement of a knowledgeable gastroenterology spe-
cialist. However, it is unclear whether patients will seek
this additional input from a HCP or pursue probiotics
outside clinical settings, as a self-management approach.
Study limitations
This study of online content related to probiotics has
several limitations that reflect our approach to defining
an appropriate sample. First and foremost is the chal-
lenge of characterizing the ever-changing information
available on the Internet. By taking snapshots of relevant
websites within a defined time period we were able to
minimize the amount of change that may have occurred
during data collection and analysis. Subsequent searches
of Internet content returned a similar set of websites,
suggesting that this information may be reasonably
stable. We did not assess the stability of this information
formally, however, which is a limitation of our approach.
In addition, our analysis of website content, which
employed well established qualitative methods and
duplicate analysis by two independent coders, has the
potential to introduce human error or evaluator bias.
Finally, our approach focused narrowly on website con-
tent and did not consider how individuals who are
exposed to this information may understand or use the
information presented. Although not within the scope of
our study, our findings highlight the need for additional
research examining how patients interpret online
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based on that information.
As ever larger volumes of information are available
directly to patients via the Internet, one of the greatest
challenges facing HCPs is to stay current with the many
health-related messages that patients may encounter
outside traditional clinical settings. Although this chal-
lenge is not unique to gastroenterology, the marketing
and direct availability of probiotic products combine to
create additional challenges in maintaining good com-
munication between patients and their HCPs.
Our results suggest that the combination of directive
product branding, unsubstantiated claims of health
benefit on Internet websites, and direct patient access to
probiotics, should be cause for concern among gastroen-
terologists. The messages patients receive from Internet
websites may require that gastroenterologists and other
HCPs revisit their patients’ expectations about probiotics
and provide a more scientifically grounded and balanced
overview of their therapeutic value. These discussions
should aim to clarify the potential benefits and risks of
probiotics for individuals with chronic GI diseases, high-
lighting potential differences in the benefit-to-risk pro-
files of probiotic usage for healthy consumers in
comparison to patients with chronic GI diseases. Gastro-
enterologists may also find it helpful to direct interested
patients to well established sources of health information
that are free of commercial influence. By initiating these
discussions, gastroenterologists and other patient educa-
tors can help to establish realistic expectations about
probiotics.
Endnotes
a According to MacMillan Dictionary a content farm
is, “A website which publishes huge volumes of low-
quality content.”
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